2019
Identification of novel diagnostic markers for sinonasal undifferentiated carcinoma
Takahashi Y, Gleber‐Netto F, Bell D, Roberts D, Xie T, Abdelmeguid AS, Pickering C, Myers JN, Hanna EY. Identification of novel diagnostic markers for sinonasal undifferentiated carcinoma. Head & Neck 2019, 41: 2688-2695. PMID: 30932264, DOI: 10.1002/hed.25748.Peer-Reviewed Original ResearchConceptsSinonasal squamous cell carcinomaSinonasal undifferentiated carcinomaUndifferentiated carcinomaDiagnostic markerNew diagnostic molecular markersSquamous cell carcinomaDistinct pathologic entityPotential therapeutic targetNovel diagnostic markerNew diagnostic markersSNSCC patientsNeuroendocrine featuresCell carcinomaHistopathologic markersSquamous lineagePathologic entityUndifferentiated tumorsAggressive cancerTumor specimensTherapeutic targetOncology panelUnsupervised cluster analysisCarcinomaPatientsMarkers
2011
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor
Cocco E, Varughese J, Buza N, Bellone S, Lin KY, Bellone M, Todeschini P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Carrara L, Tassi R, Pecorelli S, Lockwood CJ, Santin AD. Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor. Clinical & Experimental Metastasis 2011, 28: 689-700. PMID: 21725665, PMCID: PMC3697933, DOI: 10.1007/s10585-011-9401-0.Peer-Reviewed Original ResearchConceptsOvarian cancer cell linesTissue factorCancer cell linesOvarian tumorsOvarian cancerCell linesOverexpression of CD59Targeting tissue factorClear cell histologyStandard treatment modalityExpression of TFEffect of complementNovel therapeutic agentsTissue factor expressionRNA-mediated knockdownEOC cell linesCell histologyOvarian diseaseΓ-immunoglobulinPrimary EOCTreatment modalitiesPhysiologic dosesInterleukin-2Undifferentiated tumorsCD59 expression
2003
ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.
Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. Journal Of Clinical Oncology 2003, 21: 3226-35. PMID: 12947056, DOI: 10.1200/jco.2003.10.130.Peer-Reviewed Original ResearchConceptsThyroid carcinomaResult of diseasePoor prognosisRas mutationsTumor differentiationK-ras codon 13 mutationDifferentiated thyroid carcinomaCodon 13 mutationsAggressive cancer behaviorAggressive tumor phenotypeFollicular cell derivationN-RAS mutationsClinicopathologic featuresIndependent predictorsUndifferentiated carcinomaThyroid cancerPoor survivalUndifferentiated tumorsPatientsCarcinomaActivating mutationsCancer behaviorSignificant associationTumorsRas tumors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply